The MST1R (RON) kinase is overexpressed in >80% of human pancreatic cancers, but its role in pancreatic carcinogenesis is unknown. In this study, we examined the relevance of Mst1r kinase to Kras driven pancreatic carcinogenesis using genetically engineered mouse models. In the setting of mutant Kras, Mst1r overexpression increased acinar-ductal metaplasia (ADM), accelerated the progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the accumulation of (mannose receptor C type 1) MRC1+, (arginase 1) Arg+ macrophages in the tumor microenvironment. Conversely, absence of a functional Mst1r kinase slowed PanIN initiation, resulted in smaller tumors, prolonged survival and a reduced tumor-associated macrophage content. Mst1r expression was associated with increased production of its ligand Mst1, and in orthotopic models, suppression of Mst1 expression resulted in reduced tumor size, changes in macrophage polarization and enhanced T cell infiltration. This study demonstrates the functional significance of Mst1r during pancreatic cancer initiation and progression. Further, it provides proof of concept that targeting Mst1r can modulate pancreatic cancer growth and the microenvironment. This study provides further rationale for targeting Mst1r as a therapeutic strategy.
Introduction
Over the last several years, the genetic alterations that govern pancreatic carcinogenesis have been wellcharacterized and multiple genetically engineered mouse models of pancreatic cancer have been developed based on known driver mutations [1] [2] [3] [4] . Disappointingly, however, our ability to translate these discoveries into impactful therapies remains slow and yet overall, less emphasis has been placed on downstream changes in gene and protein expression, often because these changes are dynamic, illdefined, and therefore of unclear significance.
The upregulation of MST1R tyrosine kinase expression is a molecular event of particular interest in many epithelial neoplasms, as it can mediate oncogenic phenotypes and addiction to KRAS signaling [5, 6] . Additionally, MST1R signaling has been shown to promote alternative activation of macrophages, which are potently immunosuppressive. Thus, MST1R on tumor cells and in tumor-associated macrophages is potentially targetable [7] . However, it remains unclear whether MST1R signaling actually promotes pancreatic cancer progression or if MST1R overexpression merely represents an epiphenomenon.
To address this question, we utilized mouse genetic gain and loss of function approaches. For Mst1r overexpression, we created a transgenic mouse strain to express Mst1r, in a pancreas-specific manner while we used a Mst1r knock-in strain containing a targeted deletion of the tyrosine kinase signaling domain to study loss of Mst1r function. These studies reveal that in the setting of oncogenic Kras, Mst1r accelerates pancreatic duct neoplasia and progression to adenocarcinoma, though it is not absolutely required, and that functional Mst1r kinase results in increased tumor macrophage content and changes in polarization. Mst1r expression was associated with increased expression of its cognate ligand, Mst1. Additional studies in an orthotopic model demonstrate that loss of Mst1 expression, also resulted in reduced tumor growth associated with macrophage polarization toward the M1 state, suggesting that targeting Mst1/ Mst1r signaling warrants continued investigation.
Results

Mst1r expression accelerates pancreatic carcinogenesis
To study the effects of Mst1r expression on pancreatic duct carcinogenesis, we developed a transgenic mouse to direct pancreas-specific expression of the wild-type Mst1r protein using a Mst1r murine minigene driven by the Pdx-1 promoter utilized in our Pdx-1-cre strain (Pdx-1-Mst1r) (Supplementary Fig. 1A ) [4] . Founder Pdx-1-Mst1r mice demonstrated 2-fold greater expression of Mst1r protein compared to normal pancreas ( Supplementary Fig. 1b) . A cohort of 32 Pdx-1-Mst1r mice were aged to 18 months. Fourteen animals were sacrificed at approximately 10 months secondary to severe dermatitis. Pdx-1 is expressed in terminally differentiated keratinocytes in the spinous layer of the epidermis, suggesting that Mst1r overexpression in the skin of these animals resulted in dysregulated inflammation [8] . No overt histopathologic changes were evident in the pancreata of these animals. Remaining mice were sacrificed at 18 months of age. While no overt pancreatic neoplasia developed in 17 mice, 1 animal developed a moderately-poorly differentiated primary pancreatic ductal adenocarcinoma with liver metastases ( Supplementary Fig. 1C-I ). Immunofluorescent staining for the epithelial marker CK-19 demonstrated ductal structures in both the primary pancreatic tumor and liver metastases ( Supplementary Fig.1H-I ).
Since the majority of human pancreatic cancers harbor mutant Kras, we were most interested in studying the effects of Mst1r signaling in this setting. Thus, Pdx-1-Mst1r mice were bred to LSL-Kras G12D mice to yield mice (KR), which were then bred with Pdx-1-Cre to yield the compound strain termed, KRC, that overexpressed Mst1r in the pancreas in the presence of mutant Kras.
Animals were sacrificed at times ranging from 6 weeks to 15 months along with aged-matched controls (KC).
Pancreatic tissue sections were analyzed for histology and immunostained to characterize Mst1r expression. Both KC and KRC strains exhibited acinar-ductal metaplasia (ADM) and PanIN formation (Fig. 1a, b) , though ADM was considerably more prominent in KRC mice (Fig. 1c) . In wildtype mice, basal Mst1r expression was restricted to islets (Supplementary Fig. 2A ). In contrast, both KC and KRC strains demonstrated areas of Mst1r expression in ADM and PanIN lesions ( Supplementary Fig. 2B ), which were not present in wild-type pancreata. The presence of Mst1r expression in KC animals is likely secondary to known upregulation of Mst1r downstream of mutant KRAS [9] . In KRC mice, we observed an additional pattern of Mst1r expression, particularly in large lesions with extensive ADM. These areas of Mst1r expression were marked by concomitant expression of nuclear Pdx-1 consistent with presence of the Mst1r transgene (Fig. 1d) .
We next compared age-matched KC, and KRC pancreata to determine the consequences gain of Mst1r function. Lesions that developed in KC mice up to 3 months were predominantly low-grade PanIN (Fig. 1e) . In contrast, by 3 months, KRC mice developed large, abundant foci of ADM, many of which appeared to progress directly to highgrade PanIN, a phenomenon we rarely observed in KC pancreata (Fig. 1e) . These lesions demonstrated a 2-fold increase in proliferation as assayed by Ki67 qPCR (Supplementary Fig. 2C ). At later timepoints (6-9 months), KRC pancreata consistently contained more advanced PanIN than KC controls ( Supplementary Fig. 2D , n = 6, p < 0.05). In fact, 9-month KRC pancreata were nearly replaced with high-grade PanIN and invasive cancer, while lesions in KC pancreata remained predominantly low grade (Fig. 1e) . The survival of KRC mice was markedly reduced as compared to KC animals, in which median survival was not reached (Fig. 1f , 95% CI 43-51 weeks). While we did observe liver and lung metastases in KRC mice as early as 3 months, it appeared that local disease progression was the most common cause of early lethality. Taken together, these results demonstrate that Mst1r accelerates both the initiation and progression of Kras-mediated pancreatic duct neoplasia in the mouse.
Loss of functional Mst1R kinase slows progression to pancreatic cancer
After finding that Mst1R kinase overexpression results in acceleration of pancreatic duct neoplasia, we sought to determine if Mst1r was required for progression to pancreatic cancer. Loss of function studies were conducted using mice with a targeted deletion of the tyrosine kinase signaling domain of the receptor, Mst1r TK −/− (referred to as TK −/− ), created via a knock-in-out strategy [10] . Note that while, gain of function studies were conducted on a 129/B6 hybrid background, loss of function studies were conducted on a pure C57/B6 background with paired littermates. TK −/− mice were bred to LSL-KRAS G12D and Pdx-1-Cre mice ultimately, yielding KTK −/− C, a strain bearing pancreas-specific expression of mutant Kras with a functionally inactive Mst1r kinase. In stark contrast to KC mice, PanIN initiation and progression was delayed in KTK −/− C mice. In these mice, sparse PanIN were apparent at 3 months of age, and those that were present were low grade (Fig. 1e) . In KTK −/− C mice, PanIN began to appear regularly at approximately 6 months, were predominantly low grade and these persisted well beyond 12 months with delayed progression to invasive cancer (Fig.  1e) . The survival of KTK −/− C mice significantly exceeded that of KC littermate controls (p = 0.02) (Fig. 1g) . While we did observe eventual progression to carcinoma in some animals, total pancreas weight in KTK −/− C was reduced by 40% ( Supplementary Fig. 2E ) and tumor formation in KTK −/− C was much more focal as compared to KC in which multiple areas of the pancreas were involved by invasive carcinoma ( Supplementary Fig. 2F ). Thus, Mst1r function is not required for, but does significantly accelerate progression to pancreatic cancer.
Mst1r signaling alters macrophage polarization
In normal biology, Mst1r signaling results in attenuation of inflammation, by promoting changes in macrophage polarization from an "M1" and toward an "M2" state, as characterized by increased expression of M2 cell surface markers such as CD163 and MRC1 [11, 12] . During our examinations of pancreatic histology from the gain and loss of function Mst1r strains, we noted clear differences in the immune cell infiltrates. We, therefore, characterized the number of F4/80+ macrophages and found a marked increase in KRC pancreata compared with KC at 6 months of age (Fig. 2a) . In comparing KC to KTK −/− C mice, the difference in macrophage accumulation was apparent even earlier, as macrophages are almost completely absent from KTK −/− C pancreata until 3 m of age (Fig. 2b) . To more rigorously assess macrophage content, we examined macrophage content in the three strains using immunofluorescent double-labeling with F4/80+ and CD68+. This study confirmed the quantity of double-labeled cells correlated with increasing expression of functional Mst1r kinase using strain-specific background controls (Supplementary To further characterize the macrophage content, we examined pancreatic and splenic tissues from KC and KRC mice using multi-color flow cytometry [13] . We observed comparable infiltrates of CD45+CD11b+Gr1 lo myeloidlineage cells in KRC and KC animals, in both pancreatic and splenic cell suspensions (Fig. 2e) . After identifying the fraction of CD45+CD11b+Gr-1 lo infiltrating cells, we then further characterized their expression of CD11c, a marker of inflammatory macrophages, and MRC1, another marker of immunosuppressive, tumor-associated macrophages [14, 15] . Similar to our IHC studies, we observed the fraction of macrophages expressing cell surface markers indicative of an immunosuppressive phenotype (MRC1+) were significantly greater in KRC than in KC pancreata, while the fraction of CD11c+ macrophages was significantly greater in KC than in KRC pancreata (Fig. 2f ). Given our prior observations that KC pancreata develop increasing Mst1r expression associated with PanIN progression, we determined the relative quantity of Mst1r expression by Q-RT-PCR in order to characterize the relationship of macrophage phenotype to Mst1r expression. This analysis revealed that, independent of strain, high Mst1r expression was associated with a significant increase in the percentage of double positive MRC1+/CD11c+ macrophages as compared with tissues that had low Mst1r expression (p = 0.01) (Fig. 2g) .
To further characterize macrophage phenotypes, we performed immunofluorescent staining of KRC pancreatic tissues using the markers F4/80, MRC1, MHC II, and arginase I. Staining revealed that F4/80+/MRC1+ macrophages had a distinct morphology. These cells were small, round, and were frequently embedded in dense fibrous stroma surrounding the neoplastic cells ( Supplementary Fig.  4A ). Additionally, these cells expressed arginase I, a functional marker of the immunosuppressive tumor-promoting macrophages ( Supplementary Fig. 4B ) [16] . We then stained these tissues for expression of MHC II, a marker of inflammatory macrophages with antigen presentation capacity [15] . In contrast to MRC1+ macrophages, MHC II + cells were much larger with vacuolated cytoplasm suggestive of phagocytic activity and antigen-presenting capability ( Supplementary Fig. 4C ). Multiple areas of F4/80 +cells were identified primarily in KRC pancreata, a result consistent with our flow cytometry data that demonstrated an increased number of double positive MRC1+/CD11c+ macrophages in tissues with high levels of Mst1r expression. Additionally, many of these macrophages co-stained with Ki67, a marker of active replication ( Supplementary  Fig. 4D ).
KPC mice have been shown to develop splenomegaly secondary to extramedullary hematopoiesis and accumulation of splenic CD11b+Gr1 lo myeloid-derived suppressor cells [16, 17] . We next analyzed the spleens of KRC and KC animals and observed a similar pattern of CD11b+Gr1 lo expression. However, we did not observe any accumulation of either CD11c+ or MRC1+ macrophages in the spleen of KRC or KC animals, strongly suggesting that the differentiation of these macrophages is a result of soluble factors present within the tumor microenvironment ( Supplementary Fig. 4E ).
Mst1-Mst1r signaling attenuates the M1 macrophage state, but does not independently drive M2 differentiation in vitro
To further investigate if the alterations in macrophage phenotype observed were due to Mst1r signaling, we next examined if ligand-induced Mst1r activation was capable of altering macrophage polarization in vitro. Bone marrowderived macrophages were treated with either Mst1r ligand, Mst1, or tumor-conditioned media from a murine pancreatic cancer cell line, LMP, that expresses Mst1r [18] . Macrophages were treated with either IL-4 to polarize toward the immunosuppressive "M2" state (measured by expression of TGF-β and arginase-1) or IFN-γ LPS to induce an inflammatory "M1" state (measured by expression of IFN-γ, IL-12β, and inducible nitric oxide synthase (iNOS) [19] . Mst1 stimulation inhibited the expression of IFN-γ IL-12 and iNOS but did not induce expression of arginase I or TGF-β (Fig. 3a, b) . Thus, in this experimental setting, exposure to Mst1 strongly attenuated inflammatory M1 polarization, but did not fully induce an immunosuppressive M2 phenotype. LMP-conditioned media, however, was capable of inducing M2 differentiation (Fig. 3b) , suggesting that signals in addition to Mst1r activation are required to fully drive polarization toward the M2 phenotype.
Mst1r activates an autocrine/paracrine positive feedback loop
We next sought to determine how Mst1r signaling in the epithelial tumor cell was effecting changes in macrophage state in the pancreatic tumor microenvironment. Given the effects of Mst1 on macrophage polarization, we hypothesized that Mst1r overexpression may in fact result in upregulation of Mst1 expression and secretion. To explore this, we derived multiple epithelial cell lines from tumors arising in KC and KRC pancreata and characterized their Mst1r and Mst1 expression by Q-RT-PCR. These studies revealed that Mst1r-expressing lines demonstrated 10-to 60-fold increases in Mst1 expression as compared to Mst1r negative lines (Fig. 4a) . Additionally, we used a luciferase reporter assay to interrogate whether the Mst1r promoter was activated in response to Mst1 stimulation in multiple murine pancreatic cancer cell lines (PanIN 4313 and LMP). We found a significant increase in Mst1r transcription when stimulated with Mst1, with a positive regulatory response element located between −335 and −485 bp within the Mst1r promoter (Fig. 4b, c) . We similarly observed an increase in Mst1r transcript after bone marrow-derived macrophages were exposed to Mst1 (Fig. 4d) . Immunostaining for Mst1 in pancreatic tissues confirmed Mst1 expression in epithelial cells with increased frequency/ intensity in KRC vs. age-matched KC mice (Fig. 4e) . Finally, we screened tissue lysates for Mst1 protein levels and found significantly higher levels of Mst1 during disease progression ( Supplementary Fig. 5A, B) . Together, these data suggest that increased Mst1r expression results in increased expression of Mst1 by both pancreatic cancer cells and macrophages.
Mst1/Mst1r knockdown significantly inhibits tumor growth in vivo
To further test the hypothesis that Mst1r signaling from the epithelial tumor cell influences the tumor microenvironment, we utilized lentiviral shRNA to achieve knockdown of Mst1 expression in murine LMP cells (Fig. 5a ). The LMP pancreatic cancer cell line, derived from liver metastases of KPC mice, is highly tumorigenic when xenografted into the pancreata of syngeneic B6/129 F1 hybrid mice [18] . While Mst1 deficient cells were able to proliferate in vitro, they did proliferate more slowly than Mst1 intact cells (Supplementary Fig. 5C ). Both lines were able to form tumors after orthotopic injection, however, there was a profound reduction in tumor size from Mst1 deficient versus Mst1 intact lines (Fig. 5b) . We next performed flow cytometry on these tumors to determine the ratio of F4/80+/CD11c+ to F4/80+/MRC1+ expressing macrophages. Notably, the number of MRC1+macrophages was markedly reduced in Mst1 deficient LMP tumors (p = 0.03), suggesting that Mst1 secreted into the tumor microenvironment modulates macrophage polarization (Fig. 5c) . In orthotopic tumors, immunostaining for CD3+ T cells revealed marked infiltration throughout Mst1 deficient tumors, as compared to controls in which T cells were observed nearly exclusively at the periphery (Fig. 5d) . When we repeated this experiment in immunodeficient NSG mice, Mst-1 deficient tumors grew faster causing earlier lethality (data not shown), suggesting that an adaptive immune response was at least in part, responsible for growth suppression in the absence of Mst1-Mst1r signaling. Together, with our prior findings, these results suggest that Mst1r expression by pancreatic cancer cells results in secreted Mst1 protein that is then (Fig. 6a) .
Mst1r expression correlates with increased Ccl2 secretion by pancreatic cancer cells
Finally, we took advantage of the LMP Mst1/Mst1r knockdown cell lines to try and identify chemokines which may mediate the Mst1r related accumulation of macrophages in the pancreatic tumor microenvironment. We performed an ELISA to measure cytokine/chemokine levels on conditioned media from LMP control and knockdown cells. This revealed that an 8 fold reduction in the level of Ccl2 in the absence of Mst1/Mst1r expression (Fig. 5e) . To further evaluate this finding, we assayed for mRNA levels of Ccl2 in 3-month old pancreata from KRC and KTK −/− C mice. This confirmed a greater than 2-fold reduction in Ccl2 mRNA in KTK −/− C versus KRC mice (Fig. 5f ). As Ccl2 has been shown to mediate localization of bone marrowderived monocytes to the pancreatic tumor microenvironment, these findings suggest Mst1r mediated secretion of Ccl2 is at least partially responsible for our observations that macrophage content correlated with the level of functional Mst1r signaling [20, 21] . 
MST1R expression is associated with poor outcomes in human pancreatic cancer
To determine whether our findings regarding the relevance of Mst1r signaling in the mouse were relevant to human disease, we examined gene expression data from two independent cohorts. We first analyzed a publicly available dataset containing a gene expression profiling of 125 human primary pancreatic cancers and 46 normal pancreas (GSE71729). We confirmed MST1R overexpression in cancers compared with normal pancreas (data not shown). Interestingly we found that patients with a high expression of MST1R had a significantly worse overall survival (p = 0.0285). Analysis of the TCGA's pancreatic cancer cohort confirmed the association between high MST1R expression and poor overall survival (p = 0.0009) and also revealed that high expression of MST1R was associated with poorer disease-free survival (p < 0.0001) (Fig. 6b, c) . 
Discussion
The MST1R kinase is overexpressed in human pancreatic cancer yet its contribution to pancreatic carcinogenesis remains unknown. In this study, we examined the consequences of gain and loss of Mst1r function in genetically engineered mouse models of pancreatic carcinogenesis initiated by mutant KRAS, widely accepted as a relevant model of human disease. Mst1r gain and loss of function each modulated pancreatic carcinogenesis, resulting in significant changes in survival. Mst1r associated carcinogenesis was marked by: (1) earlier onset of ADM that appears to progress rapidly to high-grade PanIN, (2) More rapid progression to invasive cancer, and (3) modulation of the immune microenvironment toward a tumor permissive phenotype.
Given the predominantly embryologic expression of the Pdx-1 promoter, the initial degree of Mst1r overexpression in the KRC compound strain is modest. As expected, we identified a progressive increase in Mst1r expression in KC mice, consistent with its putative role as a Kras effector [6] . The increasing expression of Mst1r in Kras mutant mice is important to highlight because they bias the experimental results towards the null hypothesis, when comparing KRC to KC mice, making the differences we observed more noteworthy. It is clear from our studies, however, that while Mst1r promotes disease progression in the setting of oncogenic Kras, it is not absolutely required for pancreatic carcinogenesis. In loss of function studies, we observed an obvious delay in disease progression and a modest, though statistically significant improvement in survival. Concordant with these findings, we observed a smaller tumor burden in the absence of Mst1r kinase activity. Importantly, mining of two independent databases revealed that high levels of MST1R expression are a poor prognostic factor for survival in pancreatic cancer patients. These findings are in contrast to a prior report that failed to find MST1R prognostic for survival [22] . This disparity may be at least partially explained by some differences in methodology between the studies. The prior study initially characterized MST1R expression by immunohistochemistry using an antibody that we have found to bind off-target antigens. The IGCC mRNA data from this study, as the authors acknowledged, also had short follow-up at the time of their analysis.
Studies in other tumor types have similarly found that MST1R signaling impacts tumor progression [23] [24] [25] [26] . One purported mechanism by which MST1R impacts tumor progression is via its expression on macrophages within the tumor microenvironment. MST1R signaling in peritoneal macrophages has been shown to drive macrophages away from immune-surveillance (the so-called "M1" state) towards an alternative, tumor-promoting "M2" phenotype via a mechanism that involves attenuation of iNOS and increased expression of arginase-1 [7, [10] [11] [12] . We, therefore, hypothesized that in addition to its effects on the epithelial tumor cell, MST1R signaling may affect pancreatic carcinogenesis indirectly by altering the polarization of infiltrating myeloid cells and/or tissue-resident macrophages in the tumor microenvironment towards a tumorpromoting, immunosuppressive phenotype.
In keeping with this, we show that Mst1r overexpression in murine epithelial tumor cells is associated with upregulation of its own ligand, Mst1. These results are consistent with recent studies documenting tumor cell-specific MST1 upregulation in both mouse and human prostate cancer [27, 28] . We further found that Mst1 induces activation of the Mst1r promoter. To our knowledge, this reciprocal signaling between Mst1r expression and its own ligand, Mst1, has not been described. This finding that Mst1r signaling enhances Mst1 expression and that conversely, Mst1 knockdown is associated with decreased Mst1r expression, demonstrates the presence of a feed-forward signaling loop leading both to an autocrine effect on Mst1r-expressing tumor cells, as well as a paracrine effect on Mst1r-expressing macrophages within the tumor microenvironment. In the macrophage, Mst1-Mst1r signaling attenuates the expression of genes associated with tumor surveillance [7] . Since we observed that Mst1 stimulation is capable of attenuating the M1 phenotype, but not inducing the M2 state, this suggests that additional signals are necessary for this transition. Pancreatic cancer cell conditioned media was capable of inducing the M2 phenotype in vitro, also indicating that there are additional soluble factors secreted by tumor cells that influence macrophage state in the microenvironment. Among these, one report implicated lactate as a mediator of the M1-M2 transition [29] . The resultant skew towards the M2 phenotype is associated with increased expression of arginase-I. Interestingly, increased metabolism of L-arginine is associated with the accumulation of ornithine and proline, precursors of collagen synthesis [30] . Histologically, we observed that most MRC1+macrophages were embedded in dense stromal compartments characterized by abundant collagen deposition. In contrast, classically activated MHC II+ macrophages were not surrounded by stroma and maintained a large phagocytic phenotype consistent with their role as antigen-presenting cells. These results raise the possibility that the accumulation of alternatively activated macrophages within the tumor may result in increased arginine metabolism and collagen deposition, potentially contributing to the profound desmoplasia observed in the pancreatic cancer microenvironment. Our findings are consistent with those recently reported in a study that dissected the relative contribution of tissue resident versus bone marrow-derived macrophages to pancreatic tumor progression. In this study, it was the F4/80+MHC low subset of macrophages which were most often tissue derived, that were associated with tumor progression and fibrosis [31] . Consistent with this study, we found that F4/80+/MRC1+ macrophages frequently co-express Ki67, and therefore acquire and maintain the ability to proliferate alongside cancer cells. Our studies also suggest that Mst1r signaling in pancreatic cancer cells results in secretion of Ccl2, a ligand for the Ccr2 receptor. Ccl2 has been shown to mediate trafficking of bone marrow-derived monocytes to the pancreatic tumor microenvironment and influence tumor progression and prognosis [20, 21] . Our findings are also consistent with the findings of Gardner et al. who noted a correlation of Ccl2 in a liver injury model [32] .
These results provide evidence of a positive feedback autocrine and paracrine Mst1-Mst1r signaling axis, and thereby suggest that targeting the Mst1-Mst1r axis may not only have a direct effect on the tumor cell but may have the added benefit of therapeutic immunomodulation within the tumor microenvironment. In the rapidly evolving field of cancer immunotherapy, targeting activities of the tumorassociated macrophage has emerged as one central therapeutic arm of investigation. The two primary strategies have been; (1) to modulate the activation state of the macrophage, and (2) exclusion of the macrophage from the tumor microenvironment. Successful modulation of macrophage phenotypes will require a thorough understanding of the signals driving activation states. Our data suggests Mst1r signaling may contribute to this modulation in the pancreatic cancer microenvironment and is therefore worthy of further study as an immunomodulatory strategy in this disease.
Materials and methods
Mice
Animal protocols were approved by the UCSD Institutional Animal Care and Use Committee. PDX-1-cre, Kras LSLG12D and the Mst1r kinase deficient strain, (TK −/− ) were described previously [4, 10] . PDX-1-Mst1r animals were generated by insertion of a murine Mst1r mini-gene coding for wild type Mst1r protein under the control of the PDX-1 promoter [23] . PDX-1-Mst1r mice were screened for their pancreatic expression of Mst1r by western blot (Supplementary Fig. 1A , B). Mice with 2-fold increase in Mst1r were propagated forward. All strains were C57BL/6J except for the KrasLSL G12D , (B6/129S4). All experiments used littermate control mice and equal numbers of each gender. C57BL/6J/129S4 F1 hybrid mice were used for orthotopic implantation experiments. For animal studies group sizes were calculated by power analyses based on preliminary experiments using a significance level of 5% and a power of 80%. Animals were randomly assigned to experimental groups. The investigators were not blinded to allocation during experiments and outcome assessments. For genetically engineered mouse studies, equal numbers of male and female animals were used. Orthotopic experiments used male mice, aged 6-8 weeks.
Generating epithelial cell lines
Pancreatic tissues were harvested from KrasCre (KC) and KrasRonCre (KRC) mice. Tissue fragments were embedded in Matrigel-coated dishes and incubated at 37°C. Epithelial cells were isolated and propagated by clonal expansion. Mst1r knockdown and control lines were generated using shRNAs from Open Biosystems (Thermo Scientific) for mouse Mst1r, mouse Mst1 or scrambled control in the lenti pLKO.1 vector (Supplementary Table 1 ). Clones were isolated and analyzed for knockdown by Q-RT-PCR (Supplementary Table 2 ) and western blot (Anti-Mst1 Abcam, 1:3000 dilution).
Single cell suspensions
After sacrifice, intra-cardiac perfusion was performed with cold PBS. The body and tail of the pancreas were uniformly used for flow cytometry. The pancreatic head was placed in 10% saline-buffered formalin and paraffin embedded for histology. The body and tail were minced into 1-2 mm pieces in dissociation buffer. Single cell suspensions were incubated at 37°C for 15 min and then passed through a 70 uM filter into separation buffer containing EDTA. Cells were spun, counted and viability determined on a coulter counter.
Histology
Tissue sections were fixed overnight in 10% NBF and transferred to 70% ethanol. Paraffin embedding and cutting of tissue sections was performed by the UCSD Histology Core. Slides were baked overnight at 60°C and then either hematoxylin and eosin stained or processed for immunohistochemistry/immunofluorescence. Slides were coverslipped with Permount (Fisher Scientific) and stored at room temperature. Antibodies/dilutions for are detailed in Supplementary Table 3 .
Flow cytometry
Cell pellets were re-suspended in 0.5% BSA in PBS. 1 × 10 6 cells were stained with fluorochrome-conjugated antibodies at 4°C for 30 min. Cells were rinsed with 2 mL cold PBS and spun at 1500 rpm to pellet. Supernatant was removed and the cells were re-suspended in 200 uL of stabilizing fixative. Aqua Live/Dead Stain (Invitrogen) was used to exclude dead cells from the analysis. 2 uL of BD Fc Block per tube was added and incubated at room temperature for 5 min prior to adding antibodies. Cells were analyzed on a Canto RUO Analyzer or FACS Aria Sorter equipped with 488 Argon, 633 Hene, and 405 Violet Lasers. Analyses were performed using FlowJo software in consultation with the UCSD/VA Research Flow Cytometry Core.
Bone marrow-derived macrophage experiments
Primary murine macrophages were generated by flushing the bone marrow from the femur and tibia of C57BL/6 mice, followed by incubation for 5 days in DMEM containing 10% FBS and 10 ng/mL murine M-CSF (Peprotech). BMMs were subsequently cultured in DMEM containing 2% serum in the presence or absence of murine recombinant M-CSF (Peprotech) for 24 h.
Macrophages were then stimulated for 24 h with relevant ligands and then cells were lysed and RNA prepared using the RNAeasy Kit (Qiagen).
Quantitative RT-PCR (Q-RT-PCR)
RNA was extracted from pancreata using Trizol (Invitrogen) and quality checked by gel electrophoresis. Cell lines were plated to achieve 90% confluency. Treatment groups included DMEM Complete alone or DMEM Complete with 100 ng/ml recombinant murine Mst1 (R&D 6244-MS). Cells were incubated for the indicated times or overnight, after which time RNA was isolated using Trizol, then treated with DNAase1 (Invitrogen).
cDNA was synthesized from 1 µg of RNA using iScript cDNA Synthesis Kit (BioRad). Q-RT-PCR was performed using SoFast EvagGreen Supermix (BioRad) with cDNA corresponding to 50 ng of total RNA and 500 nM primers in a 20 µl volume. Primers (sequences detailed in Supplementary Table 2) were examined by gel electrophoresis then sequenced. Relative fold change was calculated using the 2 −ΔΔCt method with actin used to normalize. Either an untreated cell line, normal pancreas or KCE 329 cell line was used as the calibrator to generate the fold change [33] . Significance was set at 1.5-fold above or below the reference sample.
Orthotopic experiments
Six to eight-month-old F1 Hybrid male mice (B6129SF1/J mice, Jackson Laboratories, ME) were injected with 700,000 LMP cells into the pancreas using a 29 G 1/2cc syringe. Tumors originating from the injection were allowed to grow for 3.5 weeks. Mice were then euthanized with the tumor removed and either fixed in 10% NBF, homogenized in Trizol (Life Technologies, CA) for RNA extraction or flash frozen in liquid Nitrogen and stored at −80°C for future processing. . Survival curves and associated statistics were generated using GraphPad Prism. Patient stratification corresponding to high and low expression was performed using Cutoff Finder (http://molpath.charite.de/cutoff/). P-values refer to log-rank tests for survival curves and to unpaired ttest with Welch's correction for boxplot.
Gene expression analyses
Statistics
Data were analyzed using Student's t-test and ANOVA where appropriate. Survival analyses were performed using the Kaplan-Meier method. Flow cytometry data were analyzed using the nonparametric Kruskal-Wallis test. The Spearman's rho coefficient was calculated for all correlations. All statistical tests were 2-sided, and p-values are reported where appropriate. Microsoft Excel, GraphPad Prism 5, and SPSS Statistical software were used for the analyses.
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